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1Chapter 1: Introduction
Cancer is a disease that involves genetic and environmental factors. Knowledge
of the roles that genes play in a particular disease is rapidly helping us to understand
cancer biology. These functions differ significantly, for example, some genes can
contribute to determining the disease state (disease genes) while other genes can
interact with particular environmental factors in causing cancer (susceptibility genes).
Identifying the roles that genes play in a disease is not an easy task, it requires
rigorous biological experiments followed by statistical and computational analyses to
interpret the data. High-throughput technologies allow monitoring cell processes at
the molecular level.
One of the molecules that are typically measured is ribonucleic acid (RNA), par-
ticularly messenger RNA (mRNA). The mRNA is used as a proxy to determine gene
expression, i.e. the process by which a gene synthesizes to a gene product. These
measurements are taken with the purpose of identifying if a gene is over-expressed or
under-expressed. Using these technologies, conventional data analysis provides a list
of differentially expressed (DE) genes. This analysis is done by comparing the gene
expression from two groups and statistically identifying the genes that are signifi-
cantly different between the groups, e.g. one group of healthy individuals versus one
group of patients with the disease under study. Lists of DE genes are widely used.
However, these lists often fail to elucidate the underlying biological mechanisms.
In the last couple of decades, several approaches have focused on the interac-
tions between genes rather than the study of individual genes. These gene to gene
interactions are captured as graphs, named signaling pathways, with genes as ver-
tices and the types of interaction on the edges. Each signaling pathway describes
a cellular process and contains the genes and interactions that are involved in this
process. Researchers have been storing the knowledge about various pathways into
2many publicly available databases, such as Kyoto Encyclopedia of Genes and Genomes
(KEGG) [74], Biocarta [14], and Nature Pathway Interaction Database (NCI) [127].
Given the availability of such collection of pathways, researchers now could iden-
tify the pathways that are significantly impacted by a given condition. Identifying
pathways instead of genes increases the explanatory power and gives us a better un-
derstanding of the underlying biological phenomenon [77, 79, 102]. Many pathway
analysis methods have been developed to identify enriched or differentially regulated
pathways [9, 12, 44, 47, 137]. These methods can be divided into three different
categories: over-representation analysis (ORA), functional class scoring (FCS), and
pathway topology methods (PT) [41, 120].
The over-representation analysis (ORA) [141] identifies the pathways with differ-
entially expressed genes significantly greater than expected by chance. This approach
ignores all the gene interactions and assumes gene independence, resulting in an in-
correct hypothesis testing and thus leading to biased results. Functional class scor-
ing (FCS) methods, such as Gene Set Enrichment Analysis (GSEA) [137] and Gene
Set Analysis (GSA) [44], do not assume independence between genes [18, 35]. The
hypothesis of FCS methods states that well-coordinated small changes in relevant
genes can also have significant effects on pathways besides large changes in individual
genes. However, these approaches still do not take into consideration the interactions
between genes as described by the pathways, resulting in information loss which in
turn leads to both false positives, as well as false negatives [41]. Topology-aware
approaches, such as Impact Analysis [41, 140], analyze the pathways as graphs and
take into consideration the type and direction of each gene-gene interaction.
Pathway analysis methods using gene expression (mRNA) have achieved remark-
able results [9, 12, 44, 47, 77, 79, 102, 137]. However, mRNA alone is unable to
capture the complete picture of cell processes, as other entities also play important
roles. For instance, microRNAs (miRNAs) are newly discovered gene regulators that
3play a crucial role in diagnosis and prognosis for different types of cancer [88]. miR-
NAs are small RNA molecules capable of suppressing protein production by binding
to gene transcripts. In fact, more than 30% of the protein-coding genes in humans are
miRNA-regulated [89]. Given all the evidence of the miRNA’s relevance, hundreds
of thousands of miRNA targeting genes interactions have been experimentally vali-
dated and collected in public databases such as mirTarBase [65], miRWalk 2.0 [42],
miRecords [156], and TarBase 7.0 [129]. There are also several algorithms used to
predict miRNA targets [72, 85, 89] and databases with predicted interactions such as
miRanda [72], TargetScan [89], PicTar [85], and TargetRank [110].
In addition, relevant work has been done to elucidate the important interplay
between miRNAs and biological pathways [4, 19, 64, 65, 107, 148]. These studies
focus on different directions, some methods search for pathways that are targeted
by a particular miRNA [4], and others perform pathway analysis using just miRNA
expression, such as mirTar [64, 65] and DIANA-miRPath [148]. Other methods incor-
porate both mRNA and miRNA for pathway analysis [19, 107]. The earliest tool that
implements mRNA-miRNA integration is the miRNA and mRNA integrated analysis
(MMIA) [107] which performs Gene Set Analysis (GSA) of the down-regulated genes
that are targeted by up-regulated miRNAs. However, as mentioned before, GSA does
not take advantage of the knowledge captured by the pathway topology. The state-of-
the-art approach for miRNA-mRNA pathway analysis method is microGraphite [19]
which uses an empirical gene set approach. microGraphite’s primary goal is the iden-
tification of signal transduction paths that are mostly correlated with the condition
under study [97]. Functional analysis methods that include miRNA are still needed
to enhance the knowledge on disease gene regulation [28].
The major drawback of current approaches is that most of them do not take into
consideration the knowledge about the interactions between the genes, as well as be-
tween genes and miRNAs. In this thesis, we present mirIntegrator, a topology-aware
4approach that systematically integrates miRNA and mRNA expressions to identify
pathways that are significantly impacted by the studied condition. Our framework
is flexible and allows users to integrate signaling pathway databases with miRNA-
mRNA interaction databases to produce miRNA-augmented pathways. Here we show
that pathway analysis performed on these augmented pathways offer more statistical
power than performing analysis on gene-gene pathways. Our augmented pathways
offer a more comprehensive view and a deeper understanding of complex diseases.
This thesis encloses three contributions: a tool for integrating miRNA into signal-
ing pathways (mirIntegrator) [33], a publicly available miRNA-augmented pathway
database (mirAP), and examples of applying such augmented pathways to pathway
analysis [34, 32, 109]. Our pathway analysis pipeline uses mirAP and adapts Impact
Analysis (IA) [41, 140], a topology-aware pathway analysis method previously devel-
oped by our group. To demonstrate the advantage of our method, we analyze nine
real datasets studying seven different diseases with mRNA and miRNA expression.
We show that the proposed approach is able to identify the pathways that describe
the underlying conditions as significant. We compare our integrative method with
the traditional Impact Analysis and the state-of-the-art approach microGraphite [19].
The proposed method produces p-values and rankings of the disease pathways signifi-
cantly smaller than those obtained without data integration as well as those obtained
using microGraphite.
5Chapter 2: Related work
2.1 Biological background
This section provides a basic background in molecular biology which is key to
understand our proposed method. In particular, we present the central dogma of
molecular biology and introduce the function of microRNAs (miRNAs).
Molecular biology can be defined as the study of life at the molecular level. It is
an interdisciplinary approach that combines genetics (i.e. the study of heredity) and
biochemistry (i.e. the study of the chemistry of living things). Here, we are interested
in the molecular biology of the genes rather than other components of the cell, i.e.
the study of genes, how they translate to proteins, and its clinical significance. For
example, if we were interested in studying human skin cells we would consider both
disciplines: genetics and biochemistry. The genetics of human skin would focus on
identifying genes that have an influence on skin traits, such as the human TYRP1 gene
and the mutations in this gene that are associated with oculocutaneous albinism type
III [126] for example. The biochemistry of skin describes the chemical compounds
found in the skin, such as melanosomal proteins: tyrosinase, tyrosinase-related protein
1, and DOPAchrome tautomerase [131]. Finally, a comprehensive study would include
the TYRP1 gene, the regulatory mechanisms for which the gene translate into the
tyrosinase-related protein 1, and how these gene and protein relate to the occurrence
of oculocutaneous albinism type III [83].
Figure 2.1 illustrates a simple representation of the flow of genetic information
from genes to proteins. This process is known as the central dogma of molecular
biology which has two main steps: translation and transcription. First, a piece of
information in the DNA (a gene) is transcribed into messenger-RNA (mRNA) in the
cell nucleus. Then, the mRNA is transported to the cytoplasm to be translated into a
polypeptide chain (protein) by the action of a ribosome and multiple transfer-RNAs.
6Figure 2.1: The central dogma of molecular biology.
Credit: Nicolle Rager, National Science Foundation
The input material of transcription is deoxyribonucleic acid (DNA). The genetic
information necessary for cell functioning is carried in the form of DNA which is made
up of nucleotides. Each DNA nucleotide contains one of these four bases: adenine (A),
cytosine (C), guanine (G), or thymine (T). These bases bind nucleic acids together
by complementary pairing. Adenine base pairs with thymine and cytosine with gua-
nine (see Figure 2.2.b). The DNA structure contains two strands of complementary
nucleotide chains forming a double helix [153] as shown in Figure 2.2.a. Typically,
DNA is represented in a linear format as a sequence of nucleotides (see Figure 2.2.c).
The output of transcription is ribonucleic acid (RNA). DNA is transcribed to
messenger-RNA (mRNA) which is transported out of the nucleus. RNA is a single
strand of nucleotides (Figure 2.3.b), where each RNA nucleotide contains one of
these four nitrogen bases: adenine (A), cytosine (C), guanine (G), or uracil (U). In
transcription, each thymine base is copied as an uracil base. Typically, mRNA is
described in a linear format as a sequence of nucleotides (Figure 2.3.c).
Each triplet of mRNA nucleotides, named codon, is translated to an amino acid
7Figure 2.2: DNA structure and sequence representation. DNA sequence is typically rep-
resented in a linear format as a sequence of nucleotides: adenine (A), cytosine (C), guanine
(G), or thymine (T).
Credit: The protein data bank (PDB:3BSE) and wiki commons.
Figure 2.3: DNA is transcribed to mRNA. a) DNA. b) mRNA structure. c) mRNA
nucleotides sequence. In transcription, each adenine (A), cytosine (C), and guanine (G)
bases are copied identically. However, thymine (T) bases are copied as uracil (U) bases.
Credit: Wikimedia commons.
8(see Figure 2.4.a.). In humans, there are 20 types of amino acids, and each amino acid
is mapped from more than one codon. Figure 2.4.b. displays a codon wheel that shows
which codon encodes which amino acid. The inner circle is the first nucleotide in the
codon, the second ring the second nucleotide and the third ring the third nucleotide.
Amino acids are shown around the wheel. The amino acids translated from an mRNA
strand bond together to form proteins, i.e. polypeptide chains. Proteins are involved
in almost all functions in a cell.
There are two main categories of genes: protein-coding genes and non-protein-
coding genes (see Figure 2.5) Protein-coding genes are transcribed and then translated
into protein. Non-protein-coding genes are transcribed but never translated; their
final product is non-coding RNA (ncRNA). Gene expression is the process by which
a particular gene information (DNA) is transformed to a gene product, i.e. either
ncRNA or protein. The basic central dogma model does not include crucial ncRNAs,
such as microRNAs (miRNAs).
microRNAs (miRNAs) are small RNA molecules of approximately 22 nucleotides
capable of suppressing protein production by binding to gene transcripts (see Fig-
ure 2.6). In fact, more than 30% of the protein-coding genes in humans are miRNA
regulated [90]. Additionally, miRNAs have been shown to play a significant role
in diagnosis and prognosis for different types of diseases [88]. Several efforts have
been done to identify mRNA-miRNA target interactions, i.e. which miRNAs regu-
late which genes. Most microRNA-target interactions are statistically predicted, and
some are experimentally validated.
Given the importance of miRNAs, hundreds of thousands of miRNA-targeting-
genes interactions have been experimentally validated and collected in public
databases such as mirTarBase [65], miRWalk 2.0 [42], miRecords [156], and Tar-
Base 7.0 [129]. There are also several algorithms used to predict miRNA tar-
gets [72, 90, 85] and databases with predicted interactions such as miRanda [72],
9Figure 2.4: Translation from mRNA to proteins.
a. mRNA codons are translated to amino acids to form proteins.
b. The standard genetic code (or translation table) shows which codon encodes which
amino acid. The inner circle is the first nucleotide in the codon, the second ring the




Figure 2.5: Gene product
Credit: Wikimedia commons.
Figure 2.6: MicroRNAs bind to mRNA molecules and prevent translation.
Credit: U.S. National Institute of General Medical Sciences
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TargetScan [90], PicTar [85], and TargetRank [110]. There are also find miRNA-
disease interaction databases [65, 70, 91] which are growing rapidly.
2.2 Current pathway analysis methods
High-throughput molecular biological methods perform thousands of simultaneous
measurements of biological molecules to observe a particular state of cells. Recent
technologies have extended the breadth of available high-throughput molecular bio-
logical data. Nowadays, most of the molecular data types are analyzed separately
which has provided important discoveries, such as biomarker identification. However,
analyzing various data types together can lead to a more consistent understanding of
cell processes [50].
The term high-throughput data is used here as large measures of genetic data
taken in a short time. These data are generated by different technologies commonly
referred as “omics technologies” which are the foundation for systems biology [117].
Omics seek to quantify, describe, and identify all of the components of cellular sys-
tems with spatial and temporal dimensions [123]. There are several data types of
high-throughput measurements from which four categories are the most important:
proteomics, transcriptomics, metabolomics, and genomics [157]. Proteomics is the
study of proteins present in cells. Transcriptomics measures all gene expression values.
Metabolomics aims for the quantification and identification of metabolites. Genomics
includes the large-scale genotyping of SNPs (single nucleotide polymorphisms). Each
of these data types is unique and provide different perspectives on the cellular pro-
cesses.
There are several computational solutions for analyzing omics data in isolated
fashion [11]. However, single data type analyses have not given enough understand-
ing for successfully perform disease diagnosis and treatment. Some of the ultimate
goals for integrating multiple-omics are the identification of pathways relevant to a
12
condition and disease subtyping.
The identification of pathways that are involved in a particular phenotype is
typically referred as pathway analysis. Identifying pathways that are relevant to a
condition is important because it gives insights that can be used to further disease
treatment or diagnosis. The standard input of pathway analysis techniques is the
log-fold change of a large set of genes (around 25,000). Fold change is computed as
the ratio of gene expression between two different groups, commonly one group of
control subjects and another group with patients. The output of pathway analysis is
a ranked list of statistically significant biological pathways. These pathways are con-
sidered to be related to the condition under study. Biological pathways are graphical
representations of common knowledge about genes and their interaction with biolog-
ical processes. In particular, signaling pathways are represented as graphs with a
set of genes as nodes and the biochemical and physical interactions as edges. These
pathways are typically made by mining the literature and then manually curating the
retrieved information [74]. Signaling processes of the cell are captured in pathways
that describe the interactions between protein-coding genes and DNA [79].
Disease subtyping is another important goal for omics integration. Generating
clinical meaningful disease subtyping is critical for prognosis and further treatment
determination. Based on statistical information and the patient’s profile, the objective
is to identify the subtype of disease that the patient more likely belongs to. The input
for disease subtyping is molecular and clinical data from several patients with the same
condition but have different outcomes. The expected output is well-identified groups
that highly correlate with the observed outcomes (e.g. a group of long-term survival
patients and another group of short-term survival patients). It is also important
to identify possible patterns that are shared among members of each subtype and
differences with other subtypes. This is commonly expressed as a clustering problem
where the main goal is to search for similarities among the data points.
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All these applications show how important is integrating various biomolecular
data types. There are more applications of data integration, such as signaling
networks reconstruction [30, 53, 81, 105] and biological networks visualization [133],
but here we focus on pathway analysis.
From the computer science perspective, the term data integration refers to the
integration of fragmented information from different physical databases or data ware-
houses and different representations. Several authors have proposed platforms and
languages to integrate databases (typically using XML) [1]. Even though data frag-
mentation is a significant problem, we are not studying here that type of data integra-
tion. In bioinformatics, the terms data integration and data fusion are synonymous.
In computer science, data fusion is referred as the process of integrating information
acquired from various heterogeneous types into a single compound knowledge. Here,
we define data integration and data fusion as the integration of knowledge without fo-
cusing on the representation. Additionally, data fusion is valuable for acquiring more
reliable information than the raw measurements from a single type of source. The
primary issue in data fusion (DF) is to provide fused data with increased correctness,
conciseness, and completeness when compared with the original disjoint data. Cor-
rectness measures whether the fused data conform to the reality of the object under
study. This occurs when more than one data source can confirm the same hypothesis
which increases the confidence of the data. Conciseness refers to the reduction of am-
biguity which means that the fused data from multiple sources have decreased the set
of hypotheses about the object of study. Finally, completeness measures the amount
of information from the fused data which increases the robustness because one mea-
surement can contribute information where others measurements are incapable. To
make this process successful, we need to define an outline for resolving conflicts. Data
conflicts can occur when there is uncertainty or when there are contradictions. Un-
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certainty occurs when there is missing information, such as gene levels not included
in the measured platform, or in a particular sample. A contradiction occurs when
there is not missing information, but the information that we can extract from one
source is completely different to the one that can be obtained from another source.
Data fusion techniques have been applied mainly to the graphical computation
context. Numerous data fusion algorithms have been developed giving users different
levels of detail. Some technologies have been categorized by the USA Joint Directors
of Laboratories [92] into three basic levels according to the amount of information
that they provide. The first level corresponds to raw data uncorrelated. The second
level, or feature level, provides a greater degree of inference and some interpretative
meaning. Finally, the third level, or decision level, delivers additional explanatory
meaning. It is designed to provide recommendations to users.
In the high-throughput biomolecular data context, data integration is typically
performed in four different manners. One is to analyze each data type separately first
and then integrate the final findings. Another manner is to pre-process each type of
data independently, then perform cross-platform normalization across the data types,
then combine the normalized figures and finally perform and overall analysis. The
third type of integration consists of performing a statistical integration. The fourth
approach is to integrate the data by modeling the data types based on the biological
meaning of the molecules and their interactions (see Figure 2.7).
For example, researchers have integrated mRNA and microRNA paired data by
analyzing each data type independently and then interpreting the results manu-
ally [25]. Sometimes the results of these experiments can lead to conflicting and
unexplained outcomes. A second scenario is given when researchers having sample-
paired data decide to merge the two data tables into a single table and analyze this
new merged table. This practice requires cross-normalization, and it is very dangerous
15
Figure 2.7: Classification of integrative methods for hight-throughput biomolecular data
because each data type has different scales, volumes, and properties.
2.2.1 Integration of multi-omics data
During the last two decades, immense progress has been made toward understand-
ing the molecular processes that are altered in cancer patients. Traditional approaches
compare gene expression levels between samples of cancer patients and normal individ-
uals. Integrating gene expression with other data types has become the new challenge
in our age. Integrative approaches have shown to be successful in finding cohesive per-
spectives of complex cellular systems [15, 87, 112]. Yet, analyzing multiple data types
is extremely difficult due to data heterogeneity and high-dimensionality. To give an
example of the magnitude of this problem, The Cancer Genome Atlas1 (TCGA) [142]
portal contains datasets from nine data levels (excluding clinical data and images)
for a total of 26 different data types (see Table 2.1). Life scientists that intend to an-
1TCGA is an effort of the National Cancer Institute (NCI) and the National Human Genome
Research Institute (NHGRI).
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Table 2.1: Data types available on TCGA.
Data Level Data Type
Microsatellite Instability (MSI) Microsatellite Instability (MSI)
DNA Sequencing Whole exome sequence
DNA Sequencing Whole genome sequence
DNA Sequencing Trace-Sample Relationship
DNA Sequencing Mutations
miRNA Sequencing miRNA sequence
miRNA Sequencing Isoform
Protein expression Protein expression
mRNA Sequencing mRNA sequence
mRNA Sequencing Exon
mRNA Sequencing Gene sequence from mRNA
mRNA Sequencing Splice
mRNA Sequencing Isoform
Total RNA sequence Total RNA sequence
Total RNA sequence Exon
Total RNA sequence Gene sequence
Total RNA sequence Splice Junction
Total RNA sequence Isoform
Array based expression Gene expression
Array based expression Exon
Array based expression miRNA
DNA Methylation Bisulfite sequencing
DNA Methylation Array based
Copy number variation SNP array
Copy number variation CN array
Copy number variation Low-pass DNA sequencing
alyze these datasets in pairs would have to perform 324 different analyses to compare
every possible pair of data types. To help biologists to analyze this complex data
flood, bioinformaticians have been developing computational methods that facilitate
the integration of multiple omics.
A vast amount of high-throughput data has been accumulated in many publicly
available repositories, such as Gene Expression Omnibus [7, 43], The Cancer Genome
Atlas [142], and ArrayExpress [17, 125]. To take advantage of this information, re-
searchers are trying to integrate data from multiple datasets and multiple measure-
ments of the same set of patients from different sources. There are two general
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directions to integrate data: i) horizontal meta-analysis and ii) vertical multi-omics
analysis [146]. Horizontal meta-analysis is also known as cross-cohort data integra-
tion. Its purpose is to integrate the same type of data from independent but related
studies. A vertical multi-omics analysis integrates multiple types of data from the
same set of patients. Both of these can also incorporate information from biological
pathways or other knowledge databases. These studies require interdisciplinary ex-
pertise, such as molecular biology, statistics, and computer science. In this thesis, we
focus on vertical multi-omics analysis and investigate integrative approaches in the
domain of pathway analysis.
2.3 Pathway analysis
This section is organized as follows. First, we briefly introduce a typical com-
parative analysis, we discuss the importance of pathway analysis using only gene
expression, and we describe the existing knowledge-based pathway analysis methods.
Third, we explain the need for multi-omics data integration to identify the impacted
pathways for a better understanding of the biological mechanisms that are relevant to
the disease under study. Finally, we summarize the main strategies used to integrate
multiple data types for the purpose of pathway analysis.
2.3.1 Pathway analysis using gene expression
High-throughput technologies for gene and protein profiling, such as DNA microar-
ray or RNA-Seq, have transformed biomedical research by allowing for comprehensive
monitoring of biological processes. A typical data analysis often yields a set of genes
that are differentially expressed (DE) when comparing patients versus healthy sam-
ples. The lists of DE genes helps to identify genes that take part in the underlying
phenomenon. However, there are two drawbacks. First, they often fail to reveal the
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underlying mechanisms [79, 145]. Second, independent experiments often yield com-
pletely different lists of DE genes, making the interpretation extremely difficult [138].
High-throughput technologies for gene and protein profiling, such as DNA microar-
ray or RNA-Seq, have enhanced biomedical research by allowing for comprehensive
monitoring of biological processes. Typical data analysis often yields a set of genes
that are differentially expressed (DE) when comparing two groups, e.g. patients with
a given condition versus normal samples. The selection of DE genes is made by
comparing the distributions of the two groups using statistical tests, such as t-test.
The obtained p-value is then compared with a chosen significance level (usually, p ≤
0.05) and the fold change is compared with a predefined threshold (< 1.5 or 2) [66].
The lists of DE genes help to identify genes that take part in the underlying phe-
nomenon. However, there are two drawbacks. First, they often fail to reveal the
underlying mechanisms [79, 145]. Second, independent experiments of the disease of-
ten yield completely different lists of DE genes, making the interpretation extremely
difficult [45, 46, 138].
To address this challenge, researchers have developed a large number of knowledge
bases. Biological processes, in which genes are known to interact with each other, are
described in pathway databases, such as Kyoto Encyclopedia of Genes and Genomes
(KEGG) [74, 111], or Biocarta [14]. Pathway analysis methods [47, 66, 79, 84, 102]
have been developed to identify pathways that are related to the condition under
study.
There are three main strategies for pathway analysis using gene expression data:
over-representation analysis (ORA), functional class scoring (FCS), and pathway
topology (PT) based methods. The input of pathway analysis in general consists
of two parts: i) the molecular measurements using a high-throughput technology,
e.g. gene expression, and ii) functional annotations of the corresponding genome,
e.g. a pathway database. Gene expression data is often presented as a matrix where
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the columns represent the samples and the rows represent genes. For example, a
DNA microarray assay [38, 52] of 20 diabetes patients and 10 healthy patients can
be presented as a matrix of 30 columns and about 20, 000 rows. Each column repre-
sents a patient while each row represents the expression of a gene across all patients.
The second input, the pathway database, is a list of known functional gene modules.
A functional module can simply be a set of genes [3, 6, 20, 23, 101, 100] that are
known to be involved in a biological process, or can be a complicated network or
graph where the nodes represent genes and the edges represent interactions between
genes [26, 73, 74, 75, 111, 98].
The earliest pathway analysis methods use the over-representation analysis
(ORA) [9, 12, 37, 40, 78, 96] to identify the gene sets that have more differentially
expressed genes than expected by chance. This approach starts by identifying genes
that are differentially expressed between the two phenotypes, e.g. disease versus con-
trol. Statistical methods for identifying DE genes include t-test [58, 116], regularized
t-test [5, 62], and linear models [135]. For each pathway, ORA calculates the prob-
ability of obtaining the same number of DE genes or more, using hypergeometric or
Fisher’s exact test [48].
The ORA approach is available in a large number of tools and has widespread
usage [79]. However, ORA has a number of limitations. First, this approach only
takes into consideration the number of DE genes and completely ignores the change
in expression, i.e. it ignores gene expression values. However, gene expression and
fold-change can be useful in assigning different weights to the DE genes. Second,
ORA typically uses the most significant genes and completely ignore other genes.
For example, genes that are marginally less significant, e.g. p-value = 0.011, are not
considered resulting in information loss. Finally, ORA assumes that the difference
in expression of a gene is independent of the other genes. However, this assumption
is invalid since biological systems are complex systems of interactions between genes
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and their products. This assumption ignores the structural correlation between genes,
resulting in incorrect hypothesis testing and thus leads to biased results.
The second class of methods in pathway analysis is the functional class scoring
(FCS). Methods in this class include the gene set enrichment analysis (GSEA) [137,
104], gene set analysis (GSA) [44], sigPathway [144], Category [71], SAFE [8],
GlobalTest [57], PCOT2 [82], SAM-GS [35], Catmap [18], FunCluster [63], and
PADOG [139]. The hypothesis of this approach is that not only large changes in
individual genes can have significant effects, but well-coordinated small changes in
functionally related genes can also have significant effects on pathways. FCS meth-
ods mainly consist of three steps. First, they calculate the gene-level statistics, i.e.
differential expression of individual genes between two phenotypes. Examples include
correlation [115], Q-statistic [57], t-test [2], or Z-score [80]. Second, they aggregate
the gene-level statistics into pathway-level statistics, one for each pathway. Existing
pathway-level statistics include Kolmogorov-Smirnov (used in GSEA) [104, 137], sum,
mean, or median of gene statistics for all genes in the pathway (used in Category) [71],
or the maxmean statistic (used in GSA) [44].
The strategy used in FCS methods offers a great improvement over ORA methods.
However, it also has several limitations [79]. First, although FCS methods do not
assume the independence between genes, they still assume the independence between
pathways. However, this is not true because a gene can function in more than one
pathway. Therefore, FCS methods fail to address the crosstalk between pathways
and thus lead to biased analysis and increasement in false positives. Second, they
do not take into consideration the interaction between genes. For example, consider
a gene that is known to interact with many other genes in a pathway. A significant
change in expression of this gene would result in a large perturbation in the pathway.
This gene should be weighted much more than a gene that does not interact with any
other genes.
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The third class of pathway analysis methods is pathway topology-based ap-
proaches (PT) [41, 55, 56, 67, 68, 120, 134, 140, 154]. Methods in this class in-
clude ScorePAGE [120], impact analysis (IA) [41], signaling pathway impact analysis
(SPIA) [140], NetGSA [134], TopoGSA [56], DEGraph [68], MetPA [154], BPA [67],
and EnrichNet [55]. These methods take advantage of the interaction between
genes provided in the pathway databases. Some PT methods, such as IA [41] and
SPIA [140], model each pathway as a directed graph, where the nodes are genes or
gene products and the edges are the known interactions between the nodes. These
methods perform two statistical tests. The first test focuses on the differential expres-
sion of genes falling on a given pathway. The p-value of this first test can be obtained
from ORA or FCS methods described above. The second test focuses on the number
of perturbation factors accumulated on the given pathway. This test is concerned
with the topological position, magnitude and sign of changes in expression of genes
in the given pathway. The null distribution of the pathway perturbation is obtained
by permuting the genes at different locations in the pathway graph. The two p-values
obtained from the two independent tests are then combined using Fisher’s method.
2.3.2 Pathway analysis using multi-omics data
Although pathway analysis using gene expression has achieved applaudable re-
sults [79], recent research has proven that integrating heterogeneous types of data
offers a more comprehensive view of complex cellular systems [106], resulted in a
wave of methods for the purpose of data integration [21, 86, 130, 152]. We divide
multi-omics pathway analysis methods into two categories: topology-aware meth-
ods and non-topology aware methods. Topology-aware approaches incorporate gene
topology and interactions between entities into the analysis, i.e. methods that make
use of nodes and edges of the pathways. Non-topology aware methods are methods
that treat a pathway as a set of genes or entities without considering their topology
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Figure 2.8: General overview of multi-omics pathway topology techniques. The input
of these techniques includes different types of molecular measurements for the same set of
patients, and pathway knowledge from the databases. The output is a list of pathways
ranked according to their statistical significance, e.g. p-values or scores.
or interactions.
Figure 2.8 shows the overall pipeline of integrative pathway analysis methods.
The input includes a set of signaling pathways and experimental data from multiple
data types coming from the same set of patients. Integrative methods output a list
of pathways ranked by statistical significance, i.e. p-value or score.
2.3.3 Topology-aware integrative methods
Topology-aware integrative methods are based on the hypothesis that incorporat-
ing the structure of biological processes on the analysis will provide better results.
We have reviewed several methods of this type [21, 86, 130, 152] and identified two
main categories, graphical extensions and probabilistic graphical models. Methods
belonging to the first category extend the existing signaling pathways with molecules
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or nodes that were not included in the original pathways. Methods belonging to the
second category transform pathways to probabilistic graphical models and include
additional relations among multiple types of data.
Methods in the first category expand the existing graphs by adding new nodes,
relations, and interactions to use traditional pathway analysis methods on the ex-
panded graphs. The added nodes and relations represent the new molecules or new
data types. After the pathways are expanded, the integrative pathway analysis prob-
lem can be mapped to the classical pathway analysis, where the original pathways
are replaced with the expanded pathways, and the gene expression data is replaced
with multi-omics data. The main advantage of this approach is that traditional meth-
ods have been evaluated and accepted by the scientific community; therefore, can be
adapted rapidly to expanded networks. The main disadvantage of this approach is
that some data types cannot be mapped directly to gene interactions because their
effect on gene expression is not completely understood, for example, DNA methyla-
tion data [59]. Given that current signaling pathway databases contain information
about gene interactions and ignore remaining data types, enhancing them is cru-
cial [113, 119].
One data type that can be easily integrated to current pathways is microRNAs
(miRNAs). miRNAs are gene regulators that have shown to play important roles
in the development of cancers and many complex diseases [88, 93]. Relevant work
has been done to elucidate the important interplay between miRNAs and biological
pathways [4, 19, 64, 65, 107, 148]. The state of the art approach for miRNA-mRNA
pathway analysis is microGraphite [19] which uses an empirical gene set approach.
microGraphite’s main goal is the identification of signal transduction paths correlated
with the condition under study [97]. microGraphite integrates miRNA and mRNA
expressions by wiring the miRNA-mRNA interactions into the formal pathway repre-
sentations. After expanding the pathway, microGraphite performs pathway analysis
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using a method previously proposed by their authors named CliPPER [97].
The pipeline of microGraphite consists of five steps. In the first step, micro-
Graphite integrates microRNAs into existing pathways downloaded from pathway
databases, such as Kyoto Encyclopedia of Genes and Genomes (KEGG) [74, 111],
Nature Pathway Interaction Database (NCI) [127], Reactome [73], or Biocarta [14].
There are two types of microRNA-target interactions that are integrated to the
pathways: in-silico predicted interactions and validated interactions. Validated
interactions are obtained from miRecords[156] and mirTarbase [65]. In the second
step, microGraphite performs pathway analysis to obtain an initial set of significant
pathways. In the third step, it carries an analysis across the significant pathways
to score the coherent paths inside the pathways. In the fourth step, microGraphite
selects the paths with the highest score and then join these paths to form a connected
network called meta-pathway. Finally, microGraphite performs pathway analysis
among the paths to identify the most significant paths. The authors validated
their pipeline on an ovarian cancer dataset, obtaining a meta-pathway that guided
biological experiments further performed by them.
Methods in the second category use graphical models, such as Bayesian networks
and factor graphs, to represent the interaction between data types and gene expres-
sion. These models are more versatile because they can describe more complex type
of interactions. These methods rely on the fact that each type of genomic data con-
tains valuable information, so integrating them in an equivalent variable makes the
analysis more complete.
An example of these approaches is PARADIGM [147]. This method integrates
and analyzes different types of genomic data by producing a single measurement
called Inferred Pathway Activity (IPA). Having an IPA per patient allows us to per-
form pathway analysis for an individual while current approaches need a group of
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Figure 2.9: An example of factor graphs. This factor graph represents a global function G
as the product of the local functions f1, f2, f3, and f4. Black squares of the graph represent
local functions or factors and circles represent variables. Each factor is a function of its
neighbor variables.
samples. In order to compute the IPA, PARADIGM connects the different types of
measurements by adding causal-effect relations and the interaction between genes in
a factor graph model (see Figure 2.9). Then, the likelihood of having a gene activated
or not in each particular cancer patient and the IPA per gene is computed by per-
forming a Bayesian inference algorithm. The method was evaluated by performing
pathway analysis in two different diseases, breast cancer and glioblastoma multiform
(GBM), and comparing the results with those obtained with SPIA [140]. The authors
claimed that PARADIGM analysis generates fewer false positives, and they were able
to identify different groups of GBM with significantly different survival profiles [147].
However, in spite of numerous efforts, we were not able to reproduce these results.
This method has been included as an official tool into The Cancer Genome Atlas
(TCGA) [142].
Figure 2.10 shows a pathway example with three nodes: MDM2, TP53, and Apop-
tosis; and two relationships: MDM2 represses TP52 and TP52 activate Apoptosis.
The fist step of PARADIGM is to represent the pathway as a probabilistic model us-
ing factor graphs (see Figure 2.9). A factor graph is a bipartite graph that represents
a global function as the product of local functions [128]. Each of the local functions
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Figure 2.10: An example of the pathway model to compute IPA [147]. The biological
pathway contains three entities MDM2, TP53, and Apoptosis. The omics data of every
entity is translated to variables in a logic representation DNA, mRNA, Protein, Protein
activity, and Apoptosis. The links among variables are labeled accoring to the logical
interpretation of the biological pathway.
is a factor and is represented in the graph as a black square. Each factor has its own
variables and the global function will be represented in terms of the overall sets of
variables. The authors represent every data type as a variable in their model. The
molecules included in the model are protein-coding genes, small compounds, protein
complexes, gene families, and abstract processes. Protein-coding genes are measured
with four data-types: copy number variation (CNV), mRNA expression (mRNA),
protein level (protein), and protein activity status (activity). In this toy example
(Figure 2.10), we have two protein-coding genes (MDM2 and TP53) and one abstract
process (apoptosis). Therefore, we have four variables per each gene and one vari-
able for the process. The authors also defined a set of labels to apply depending on
the type of relationships among components. In this example, the relationships are
“activation” and “repression” and the labels “positive” and “negative” are respec-
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tively applied. Now that the variables and relations are identified, we can construct
the factor graph. Each variable will represent a differential state of each entity in
comparison with a control level. The possible states can be activated, nominal, or
deactivated. A factor is attached to each variable and represents the expected state of
such a variable. To decide the state of the variables, a voting system will be applied
as described on Figure 2.11. For each link of a variable on the factor graph, the
algorithm starts checking the type of label assigned: minimum, maximum, positive,
or negative. If the label is minimum, the vote is computed as the minimum state
among the parent variables connected to such a link. If the label is maximum, the
vote is computed as the maximum state among the parent variables connected to
such a link. If the label is positive, the vote is the same state of the parent connected
to such a link. If the label is negative, the vote is computed as the inverse state of the
parent connected to such a link. Once the votes of all the edges are counted, the next
expected state is equal to the state with more votes. If there is a tie, the expected
state is -1.
The second step is to define the prior probability. For this, the authors use
the expectation maximization algorithm [31, 61, 99] to estimate if a particular
hidden variable is likely to be in a particular state. Once the prior probabilities
are estimated, they use a belief propagation algorithm [49] to find the maximum
likelihood that a variable is in a particular state along with all the other observations
made for the patient.
2.4 Omics integration for disease subtyping
A vast majority of the diseases develop differently making them heterogeneous.
Precise classification of patients into subtypes has important indications for medicine.
Moreover, identifying subtypes that are relevant to survival profiles or related to bi-
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Figure 2.11: Algorithm to decide if an entity is active of not based on its labels. For
each link of a variable on the factor graph, we start by checking the type of label assigned:
minimum, maximum, positive, or negative. If the label is ‘minimum’, the vote is computed
as the minimum state among the parent variables connected to such a link. If the label
is ‘maximum’, the vote is computed as the maximum state among the parent variables
connected to such a link. If the label is ‘positive’, the vote is the same state of the parent
connected to such a link. If the label is ‘negative’, the vote is computed as the inverse state
of the parent connected to such a link. Once the votes of all the edges are counted, the next
expected state is equal to the state with more votes. If there is a tie, the expected state is
-1.
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ological patterns is crucial. This is to identify more homogeneous disease subtypes
and their corresponding genetic signatures. Subtype distinction can advance diagno-
sis classification which can improve clinical decision and treatment matching. Most
methods for disease subtyping perform clustering using clinical data from patients.
These methods do not use molecular measurement and the outcome subtypes are
prone to be suboptimal [136].
A contemporary method that integrates genetic data for disease subtyping is SNF
(Similarity Network Fusion) [152]. The input of SNF includes multiple matrices for
the same set of patients, each matrix is the molecular measurement of a data type.
SNF first constructs a patient similarity matrix (PSM) for each data type based on
Euclidean distance. It then constructs a patient similarity network for each data type
where the nodes are patients and the edges are the similarity between them. It then
iteratively fuses these networks into one network that represents the overall similar-
ity between patients for the multi-omics data. In each iteration, the fused network
discards the weak similarities to eliminate contradictions. After each iteration, the
networks from multiple data types are more similar to each. The algorithm stops
when the networks are identical. Finally, a similarity-based clustering, such as spec-
tral clustering [108], is performed on the fused network to identify subtypes of the
disease.
The authors validated the discovered subtypes using Kaplan-Meier survival curves,
Cox regression [24, 143], and Silhouette score [124]. The method is compared with ex-
isting methods, such as iCluster [132] and Consensus Clustering [103]. The data anal-
ysis was done using five different cancer datasets downloaded from TCGA: glioblas-
toma multiform data (GBM), breast invasive carcinoma (BIC), kidney renal clear cell
carcinoma (KRCCC), lung squamous cell carcinoma (LSCC), and colon adenocarci-
noma (COAD). For all the five datasets and all the metrics used, SNF achieved the
best result.
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Cox log-rank test is one of the methods to decide if certain groups have clearly
different survival behavior or not. This method is used in survival analysis. Survival
analysis is performed in studies that aim to investigate the change of state of a
variable. In this context, we refer to studies that investigate life duration of the
certain sample. The basic setup for the analysis is that certain subjects (e.g. cancer
patients) are tracked over time until the event happens (e.g. death) or the subject
is lost from the sample and cannot be track anymore (e.g. patients do not return to
the center that is performing the study and the center does not know if the patient is
alive or not). Survival in this context means how long people stay in the sample. At
the beginning of the study all the subjects are in the sample; therefore, the survival
is 100%. Over time, events start happening and the survival start decreasing until
the study is over. Typically, the analysis will include a survival curve to visualize
the behavior of survival over time. It also includes hazard rates, which represent the
risk of failure or what is the chance that the event will happen before a certain time
period. In this case, the hazard is the probability of dying at a particular moment.
The dependent variable is the duration of measurement wich is a combination of
three variables the time variable (the length of time until the event happened or
being in the study), the event variable (1 if the event happened or 0 if the event
has not happened yet), and the censored variable (indicating if the measurement was
taken or not). These survival studies can have several extensions, one of these is the
use of more that one group of participants in the same study. Survival analysis can
be made for nonparametric models, parametric models, or semi-parametric models.
Nonparametric models are useful for descriptive purposes and to visualize the shape of
the survival and hazard functions before using a parametric model. Hazard curves are
nonmonotonic and survival curves are strictly non-increasing curves. There are two
estimators commonly used for non-parametric models: Nelson-Aalen estimator of the
cumulative hazard function and The Kaplan-Meier estimator for the survival function.
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Once the nonparametric model has been run, one can include some independent
variables that may affect those functions by using a parametric or semi-parametric
model. These models depend on the form of the functions. The Cox proportional
hazard model is used for estimation of semiparametric models. The cluster number is
are included on the survival analysis as an independent variable. A comparison of two
survival curves can be performed using the statistical hypothesis test named log-rank
test. It tests the null hypothesis that there is zero difference between the survival
curves. The dependent variable for this model is the hazard [13]. The p-value of the
test indicates if the difference between groups borders on the statistical significance or
not, to determine if there is strong evidence that a variable is associated with length
of survival. The Cox regression test is useful to find which variables are significant
for the complete set of samples. The Log-rank Mantel-Cox test is a test for two or
more groups and aims to tell if these groups have different survival curves. When
comparing more that two groups, correction for multiple comparisons is needed.
In SNF, the validation of label prediction was achieved by comparing SNF with
two other approaches, PAM50 and iCluster. They used breast cancer data from the
Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) [27]
and computed the Cox log-rank test p-values for each of the methods. They also
computed the concordance index (CI) [60] for discovery and validation cohort for risk
of death prediction. The authors also presented a general validation of the fused
network by comparing the Cox log-rank test p-values obtained when using individual
data types versus the fused data. For this experiment, they used the five cancer data
sets from TCGA mentioned before: GBM, BIC, KRCCC, LSCC, and COAD.
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Chapter 3: Integrating signaling pathways with
miRNA target genes: our proposed method
In this section, we propose an algorithm for integrating miRNA into signaling
pathways. The integration of miRNA into signaling pathways have multiple applica-
tions, such as pathway analysis and disease subtyping. We also describe a pipeline
to use the miRNA-augmented pathways (mirAP) in the context of pathway analysis
(PA). This analysis is used in biological studies comparing genetic samples from two
different phenotypes (e.g. disease vs. control samples). Our PA pipeline integrates
miRNA and mRNA expression data and identifies pathways that are related to the
disease under study. The standard input of pathway analysis includes gene expression
data from two different phenotypes and a set of signaling pathways. The input of our
pathway analysis includes miRNA and gene expression data comparing two different
phenotypes (e.g. condition vs. control) and a set of signaling pathways and a list of
miRNA-gene interactions.
3.1 Proposed integrative pathway analysis pipeline
3.2 Pathway analysis pipeline
The identification of pathways that are significantly perturbed in a given pheno-
type helps us understand the underlying biological processes. Traditional pathway
analysis techniques aim to infer the impact on individual pathways using only gene
expression measurements (mRNA). However, gene expression does not capture the
complete picture of the biological mechanisms involved, as many other entities play
important roles in the processes. By ignoring them, we ignore potentially crucial in-
formation. One type of these entities is microRNA (miRNA), newly discovered gene
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Figure 3.1: Workflow of pathway analysis using augmented pathways.
for different types of diseases [88].
Researchers investigating miRNA cannot perform pathway analysis using tradi-
tional techniques because current pathways datasets do not contain miRNA-target
interactions. Our pipeline fills this gap by integrating miRNAs into signaling path-
ways.
Our pathway analysis pipeline consists of three main steps (shown in Figure 3.1):
1. In the first step, we find the miRNAs that target the genes of each signaling
pathway. miRNA-targets can be identified with existing algorithms for predic-
tion of miRNA-targeting [72, 89, 85, 110] or by using databases of validated
miRNA-target interactions [65]. Our implementation allows the use of predicted
or validated interactions or a mix of both. The user can provide custom inter-
actions our use the default database that we provide with the package which is
mirTarBase [65].
2. In the second step, we augment the signaling pathways with the miRNAs iden-
tified in the first step. The output is a list of miRNA augmented pathways.
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At this point, the data integration problem is mapped to the original pathway
analysis problem for which existing methods can be applied. The difference is
that here both miRNA and mRNA expression can be taken into consideration.
3. In the third step, we apply any pathway analysis that uses fold change and p-
value as input, e.g. Over-representation analysis (ORA) [40] and Impact Anal-
ysis [41, 140]. ORA and Impact Analysis are well-known methods developed
by our group to identify signaling pathways that are impacted by the effects of
diseases. Fig. 3.1 displays the overall pipeline of our approach.
3.2.1 Impact analysis using mRNA and miRNA
Impact Analysis is a topology-aware method that combines two types of evidence:
i) the over-representation of DE genes (ORA) [40], and ii) pathway perturbation
caused by disease, as measured by propagating expression changes through interac-
tions between the genes. These two types of evidence are captured by two independent
p-values: pORA and pPERT . To calculate pORA on the miRNA augmented pathways,
we use the following information: i) the total number of entities (genes and miR-
NAs) taken into consideration, ii) the entities belonging to the augmented pathways,
iii) the entities that are differentially expressed (DE), and iv) the entities that are
differentially expressed in the given pathway. The first input is the total number of
genes and miRNAs that were measured. The second input includes the genes of the
pathway and the miRNAs that target at least one gene in the pathway. The third
and fourth inputs are calculated from the input lists of DE genes and DE miRNAs.
We perform a modified t-test [122] on both gene and miRNA expression separately.
The significance threshold to determine the genes and miRNAs that are differentially
expressed is set to 5%.
To calculate pPERT , we use the following information: i) the entities that are
differentially expressed, and ii) a graph that represents the augmented pathway. The
35
first input can be determined using the modified t-test for each data type [122] while
the second input is constructed in the first step of the approach. These two p-values
are combined using Fisher’s method [48] to get a single p-value that represents how
likely the pathway is impacted by the effect of the disease.
The combination of p-values provides a significant advantage to our approach
because we do not require additional cross-platform normalization between mRNA
and miRNA data. In other words, our method combines the p-values independently
of the technologies or platforms used to measured miRNA and mRNA. In this way,
we avoid additional statical error due to cross-platform normalization.
3.3 Proposed algorithm for pathway augmentation
Our method augments the graphical representation of original signaling path-
ways with interactions between miRNAs and their target genes. The input of this
method includes a set of signaling pathways and known miRNA-mRNA interactions
(Fig. 3.1a,b). The output is a set of augmented pathways that consists of the original
genes, the miRNAs that target those genes and their interactions. Let P = (V,E) de-
note the graphical representation of the original gene-gene pathway, and T : M → V
a function that identifies the target genes of miRNAs in M . An edge e ∈ E can be
represented as a 3-tuple e = (g1, g2, interaction). We augment the nodes and edges
of the original pathway as follows:
V¯ = V ∪ {m ∈M |T (m) ∩ V 6= ∅}
E¯ = E ∪ {(m, g, inhibition)|m ∈ V ∩M ∧ g ∈ T (m)}
We implemented this algorithm in R and published it as the Bioconductor package
named mirIntegrator (http://bit.ly/mirIntegrator). mirIntegrator is flexible and
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allows users to integrate user-specific pathway databases with user-specific miRNA-
mRNA target databases. Additionally, it generates graphical representations of the
augmented pathways (see Fig. 6.3). We integrated pathways from Kyoto Encyclo-
pedia of Genes and Genomes (KEGG) [74] (version 73) with miRNA targets from
miRTarBase [65] (version 4.5) to generate mirAP, a database of miRNA-augmented
pathways (htpp://www.cs.wayne.edu/dmd/mirAP).
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Chapter 4: Proposed miRNA augmented
pathways database
4.1 Databases needed for integration
The input to generate the augmented pathways includes a database of signal-
ing pathways and a database of miRNA target interactions. Here we describe the
databases that we used in our approach.
4.1.1 Database of signaling pathways: KEGG pathways
As described in previously we are using the Kyoto Encyclopedia of Genes
and Genomes (KEGG).We downloaded the KEGG pathways release 73.0+/01-03,
Jan 2015 (Kanehisa Laboratories). This dataset contains 149 KEGG human sig-
naling pathways. To process the original pathways in R, we parsed them into
a list of graphNEL objects using the ROntoTools package Version 1.2.0. The
users can obtain the list of KEGG human signaling pathways with the function
data(''kegg pathways''). This object contains a list of graphNEL objects where
each graph represents one KEGG signaling pathway. The name of each pathway is
its KEGG pathway identifier. A script that constructs the kegg pathways object may
be found in ‘inst/scripts/get kegg pathways.R’,
The names of the pathways are stored on a different object called names pathways.
This object contains a list of KEGG signaling pathways’ names. The names of the
pathways in human are obtained with the ROntoTools package. This object can be
loaded with the instruction data(''names pathways''). A script that constructs the
names pathways object may be found in ‘inst/scripts/get names pathways.R’, see the
example.
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4.1.2 Database of miRNA target interactions: mirTarBase
The second database needed to generate the miRNA augmented pathways is a
database of miRNA-target interactions. For this purpose we use mirTarBase [65]
which was downloaded from http://mirtarbase.mbc.nctu.edu.tw/ on 4/1/2015.
mirTarBase is a publicly available database of microRNA-target interactions in hu-
man. We downloaded mirTarBase release 4.5: Nov. 1, 2013, and made it accessible
in our package through the object mirTartBase. This object is a data.frame with
39083 interactions and nine variables. This dataset is licensed by its authors (Hsu et
al.), see http://mirtarbase.mbc.nctu.edu.tw/cache/download/LICENSE.
Even though our package includes mirTarBase, any data.frame with human
miRNA-targets interactions can be used to generate the miRNA augmented path-
ways. For this purpose, the data.frame should contain the following columns:
• miRNA: which contains the miRNA ID,
• Target.ID: contains the entrez ID of the gene targeted by the miRNA
A script which downloads the file and constructs the mirTarBase object may be
found in ‘inst/scripts/get mirTarBase.R’.
4.2 Data representation of the augmented pathways
The primary goal of our mirIntegrator package is to integrate microRNA expres-
sion into signaling pathways for pathway analysis. The first step of our pipeline is
to augment signaling pathways with miRNA target interactions. Figure 4.1 shows a
model of the expected output.
In our package, we include a list of signaling pathways augmented with miRNA
in the object augmented pathways. This object is a list of human signaling KEGG
pathways augmented with validated miRNA-target interactions from mirTarBase us-
ing our algorithm. These interactions represent the biological miRNA repression of
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Figure 4.1: Model of a miRNA-augmented pathway. Portion of the Colorectal Cancer
pathway from KEGG.
its target genes and are included in the model as negative links. The object can be ob-
tained with the instruction data(''augmented pathways''). augmented pathways
is a list of graphNEL objects where each graph is a pathway that was augmented with
miRNA-target interactions. The id of each pathway is its KEGG pathway identifier.
A script that constructs the augmented pathways object may be found in ‘in-
st/scripts/get augmented pathways.R’.
4.2.1 Using the augmented pathways: an example
We also include an example that illustrates how to use the augmented pathways.
Let us say that we are interested in finding the pathway with a fewer number of nodes
among the augmented pathways, i.e. the smallest pathway. This script is included
in the function smallest pathway. This simple function is an example of how to
navigate the genes on the list of augmented pathways. The parameter is a list of
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graph::graphNEL objects, let us call it pathways. The output is the index of the
pathway with a fewer number of nodes. The instruction to get the number of nodes
of the smallest pathway is length(smallest pathway(augmented pathways)).
4.3 Proposed graphical visualization of the pathways
mirIntegrator incorporates a functionality to produce a graphical represen-
tation of the final pathways. This functionality is useful when researchers need to
visualize the nodes that were added to the pathway. For instance, if they need to
see how the pathway of “Sulfur relay system” (path:hsa04122) has changed, they can
plot the augmented pathway using the function plot augmented pathway. Here an





Another useful function is plot change which can be used to see how much the
order of the pathways has changed. To demonstrate this functionality, the mirIn-
tegrator package includes a copy of KEGG human signaling pathways. We ob-
tained these KEGG pathways using the KEGGgraph package. A complete script
describing how this dataset was obtained included in this package on ‘/inst/script-






Figure 4.2: Example of augmented pathway. This visualization of the miRNA-augmented
Sulfur Relay System pathway was generated using the function plot augmented pathway
on our package.
See the resulting graph on Figure 6.2.
This package also includes a function to generate a pdf file with the plots of the







4.4 Script to augment signaling pathways with miRNA
The main functionality of the mirIntegrator package is the integration of miR-
NAs into signaling pathways. The input of this functionality are a set of signaling
pathways like KEGG pathways [74] or Reactome [26], and a miRNA-target interaction
database like mirTarBase [65] or TargetScan [89]. The output is a set of augmented
signaling pathways. Each augmented pathway contains the original sets of genes and
interactions plus the set of miRNAs involved in the pathways and their miRNA-target
interactions. These interactions are the biological miRNA repression to their target
genes and are represented in the model as negative interactions.
Here we show an example of the method functionality. Let us say that a researcher
needs to integrate the human signaling pathways from KEGG [74] with miRNA in-
teractions from miRTarBase [65]. The researcher must first obtain the list of path-
ways as a list of graph::graphNEL objects. The nodes of each pathway represent
the genes involved in the pathway, and the edges represent the biological interac-
tions among those genes (activation or repression). The second step is to obtain a
miRNA-target interactions dataset as a data.frame with the columns ‘‘miRNA’’ and
‘‘Target.Gene’’. Notice that the symbols used to identify the ‘‘Target.Gene’’
column on the miRNA-target interactions dataset must be the same symbols used on
the nodes of the pathways. i.e. If the genes are identified by entrezID on the path-
ways’ dataset, then the miRNA-targets dataset must identify the genes by entrezID
as well. Once the researchers have these two datasets, they can use the function
integrate mir.
To demonstrate this functionality, mirIntegrator package includes the object
mirTarBase which is a copy of the experimentally validated miRNA-target inter-
actions database miRTarBase [65]. We downloaded the miRTarBase database from
http://mirtarbase.mbc.nctu.edu.tw/ on November 11, 2016. A complete script
describing how this database was downloaded and formatted is included in this pack-
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age on ‘/inst/scripts/get mirTarBase.R’.
Here is an example of how researchers can generate the list of augmented path-




kpg <- kpg[15:20] #delete this line for augmenting all pathways.
require("mirIntegrator")
data(mirTarBase)
augmented_pathways <- integrate_mir(kpg, mirTarBase)
head(augmented_pathways)
The result is a list of pathways where each pathway is a graph::graphNEL
object. When researchers need to see the details of a particular pathway, they
can do so by only using the KEGG pathway id of the pathway of interest. For
example, the pathway “path:hsa04122” can be reached with the following instruction:
augmented_pathways$"path:hsa04122"
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Chapter 5: Software Implementation
5.1 Software features
The software mirIntegrator is implemented using the R programming language. It
is publicly available on the Bioconductor website (http://www.bioconductor.org).
The package has three main functionalities: i) integration of miRNAs into signaling
pathways, ii) graphical representations, and iii) pathway analysis using the augmented
pathways and both mRNA and miRNA data. These functionalities are documented
in the software manual (at Bioconductor.org). We also developed a GUI version for
this software using the shiny framework [22]. The source code of the graphic user
interface is available at http://datad.github.io/mirIntegrator.
5.2 Pathway analysis in R and Bioconductor
The primary goal of bioinformatics is to contribute to advances in biology by
developing and distributing tools to handle the massive dataset and perform com-
plex analyses. Making these tools available for collaborative improvement is crucial.
Projects like Bioconductor, CRAN, Bioperl, and Biopython are repositories of open
source bioinformatics and statistical tools to foster collaborative development.
The Bioconductor [54] project aims to reduce the barriers for remote interdisci-
plinary research and facilitate the reproducibility of research results. Bioconductor
packages are primarily written in R although C++ and other programming languages
can be incorporated into the packages [39]. There are several well-implemented sta-
tistical and visualization tools in R that facilitate and speed the development of new
bioinformatic tools. Bioconductor has several advantages over other projects includ-
ing: supports object-oriented programming for R, promotes modularization at the
package level, web connectivity, statistical simulation, modeling, and visualization
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support, among others.
In addition to all these advantages, Bioconductor has a peer-review process for
publication. This process increases the quality of the packages, reduces duplicity,
promotes reusability of software and data structures, and improves the quality of
documentations, vignettes, and other manuals that are included in the packages.
We implemented our algorithm in R and published it as the Bioconductor package
named mirIntegrator (http://bit.ly/mirIntegrator). mirIntegrator is flexible and
allows users to integrate user-specific pathway databases with user-specific miRNA-
mRNA target databases. Additionally, it generates graphical representations of the
augmented pathways (see Fig. 6.3). We integrated pathways from Kyoto Encyclo-
pedia of Genes and Genomes (KEGG) [74] (version 73) with miRNA targets from
miRTarBase [65] (version 4.5) to generate mirAP, a database of miRNA-augmented
pathways (htpp://www.cs.wayne.edu/dmd/mirAP). Figure 5.1 represents the graph-
ical augmentation of the colorectal cancer pathway in KEGG. Our package has three
main functionalities: i) integration of miRNAs into signaling pathways, ii) graphical
representations, and iii) pathway analysis using the augmented pathways and both
mRNA and miRNA data.
i. Integration of miRNAs into signaling pathways. By default, the package in-
cludes KEGG pathways (version 73) [74] and their augmented versions using vali-
dated targets from miRTarBase (version 4.5) [65]. However, the software also allows
users to download and augment pathways using other databases.
ii. Graphical representations. mirIntegrator is suitable to generate a number
of graphical representations. For example, Figure 4.2 shows the augmented Sulfur
relay system pathway. The nodes in green are the genes from the signaling pathways
and the nodes in black are the newly added miRNAs. mirIntegrator also generates
a visualization and statistics of the miRNAs added on each pathway. This chart
is particularly useful to analyze the overall impact that miRNA have in a set of
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Figure 5.1: Portion of the miRNA-augmented Colorectal Cancer pathway.
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pathways.
iii. Pathway analysis using augmented pathways. The final goal of the framework
is to integrate miRNA and mRNA expression for the purpose of pathway analysis.
Figure 5.2 shows a screenshot of the graphical user interface (GUI). First, users are
required to upload miRNA-mRNA sample-matched data. The datasets then can be
selected using the drop boxes. To perform the analysis, users simply click the button
Run Impact Analysis to computes the p-value for each pathway. These p-values are
then adjusted for multiple comparisons using False Discovery Rate (FDR) [10, 121].
5.3 Example of pathway analysis of miRNA and mRNA data
The main purpose of the pathways augmentation process is to analyze miRNA
and mRNA expressions at the same time. For this reason, we show here how to
analyze a multiple sclerosis datasets using the mirIntegrator package. Jernas et
al. [69] published the dataset that we analyzed. They collected heparin-anticoagulated
peripheral blood from 21 multiple sclerosis (MS) patients and nine healthy controls.
Ten of the 21 samples were used to profiled mRNA expression, and the 11 remaining
were used to profiled miRNA expression. These datasets are accessible at NCBI
GEO database [43], with accession GSE43592. We preprocessed the datasets using
the limma package [135]. For demonstration purposes, we included the preprocessed
datasets on this package.
data(GSE43592_miRNA)
data(GSE43592_mRNA)
Once researchers have the data and the augmented pathways, they can run the
pathway analysis method that they prefer. We suggest using ROntoTools pack-
age [150] because it takes into account the topology of the pathways (the method
implemented on ROntoTools is explained on [149]). We show here how to perform
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Figure 5.2: A screenshot of the mirIntegrator’s graphical user interface (GUI). Users first
upload their sample-matched mRNA and miRNA datasets. They can choose the datasets
from the drop boxes. To perform data analysis, users just press the button Run Impact
Analysis. The output of the software is a list of augmented pathways ranked according
to the joint probability of having both the observed level of enrichment as well as the
observed level of perturbation just by chance. This probability is corrected for multiple
comparisons with the false discovery rate adjustment (pComb.fdr). Other statistics, such as
p-values for the observed perturbation (pPert), raw p-value for the combined enrichment and
perturbation (pComb), and the FDR-corrected p-value for perturbation alone (pPert.fdr),
are also reported.
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keggGenes <- unique(unlist( lapply(augmented_pathways,nodes) ) )
interGMi <- intersect(keggGenes, GSE43592_miRNA$entrez)
interGM <- intersect(keggGenes, GSE43592_mRNA$entrez)
peRes <- pe(x= c(lfoldChangeMRNA, lfoldChangeMiRNA ),
graphs=augmented_pathways, nboot = 200, verbose = FALSE)
message(paste("There are ", length(unique(GSE43592_miRNA$entrez)),
"miRNAs meassured and",length(interGMi),
"of them were included in the analysis."))
message(paste("There are ", length(unique(GSE43592_mRNA$entrez)),
"mRNAs meassured and", length(interGM),
"of them were included in the analysis."))
summ <- Summary(peRes)
rankL <- data.frame(summ,path.id = row.names(summ))
tableKnames <- data.frame(path.id = names(names_pathways),names_pathways)
rankL <- merge(tableKnames, rankL, by.x = "path.id", by.y = "path.id")
head(rankL)
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Chapter 6: Method Validation
6.1 Validation outline
In this section, we present a detailed quantification of the augmented pathways and
the results of our pathway analysis pipeline using the miRNA-augmented pathways
(mirAP). For this purpose, we downloaded and augmented signaling pathways with
miRNA-gene interaction from KEGG [74] and mirTarBase[65], respectively. To vali-
date our pathway analysis pipeline, we perform pathway analysis of 9 mRNA/miRNA
sample-matched datasets using two different methods (Impact Analysis and ORA)
and show that mirAP offers a significant improvement over analyzing mRNA data
alone. We also compare the obtained results with the state-of-the-art method (mi-
croGraphite) [19].
6.2 Descriptive statistics of the augmented pathways
We augmented the KEGG pathways to analyze the change in pathways size after
introducing miRNAs. Figure 6.2 shows some statistics about the number of nodes of
each pathway before and after augmentation. We sort the pathways in an increasing
order of the number of genes in the original pathways for a clear visualization. The
red line shows the size (number of genes) of the original pathways. The average
number of genes in a KEGG pathway is 102. The blue line indicates the number
of miRNAs added to each pathway. On average, each pathway is augmented with
134 miRNAs. The green line shows the total number of both mRNA and miRNA
for each pathway after augmentation. On average, an augmented pathway has 234
entities (genes and miRNAs). In essence, the size of each pathway is approximately
doubled after augmentation. These results show that pathways are heavily regulated
by miRNAs and confirm the crucial role of miRNAs, as well as the importance of
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Figure 6.1: Evaluation scheme.
Figure 6.2: Comparison of pathway sizes before and after augmentation. The pathways
were sorted by KEGG pathway size. The red line shows the size (number of genes) of
the original pathways. The blue line shows the number of miRNAs added each pathway.
The green line shows the total number of both mRNA and miRNA for each pathway after
augmentation. On average, the size of each pathway is doubled after augmentation. Plot
generated using the function plot change.
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Table 6.1: Description of the analyzed datasets
Ref. GEO ID Pubmed Disease/Target pathway KEGGID
[76] GSE26168 21829658 Type II diabetes hsa04930
[95] GSE62699 26381263 Alcoholism hsa05034
[118] GSE35834 23987127 Colorectal cancer hsa05210
[114] GSE43797 24072181 Pancreatic cancer hsa05212
[94] GSE29250 22046296 Non-small cell lung cancer hsa05223
[36] GSE32688 22261810 Pancreatic cancer hsa05212
[69] GSE43592 23895517 Amyotrophic lateral sclerosis hsa05014
[155] GSE35389 23056502 Melanoma hsa05218
[51] GSE35982 22703586 Colorectal cancer hsa05210
being able to analyze miRNA and mRNA data together. Although the framework
was demonstrated on KEGG pathways, it can exploit information available in other
databases, such as functional modules available in Gene Ontology database [23] or
protein-protein interactions available in the STRING database [151].
6.3 Results
We analyzed nine sample-matched datasets from seven different diseases:
GSE43592 (multiple sclerosis, 10 controls, 10 cases), GSE35389 (melanoma, 4 con-
trols, 4 cases), GSE35982 (colorectal cancer, 8 controls, 8 cases), GSE26168 (type II
diabetes, 8 controls, 9 cases), GSE62699 (alcoholism, 18 controls, 18 cases), GSE35834
(colorectal cancer, 23 controls, 55 cases), GSE43797 (pancreatic cancer, 5 controls,
7 cases), GSE29250 (non-small cell lung cancer, 6 controls, 6 cases), and GSE32688
(pancreatic cancer, 7 controls, 25 cases). For each of these datasets, we used the nor-
malized expression values as found in GEO [7]. The microarray probes were annotated
according to their platform’s metadata using GEOquery [29]. Next, we estimated log-
fold-change between disease and control groups by fitting to a gene-wise linear model
using the limma package [122]. We only took into consideration mRNA and miRNA
with adjusted p-values lower that 5%. Among these significant mRNAs and miRNAs,
we chose the ones that have the highest fold-change as differentially expressed, up to
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10% of measured mRNAs and miRNAs.
The nine datasets were selected due to two important reasons. First, these datasets
have both mRNA and miRNA measurements for the same set of patients. Second, for
each of the underlying diseases, there is a KEGG pathway, henceforth target pathway,
that was created to describe the underlying mechanisms of the disease. To demon-
strate the advantage of the miRNA data integration, we compared the use of the
original KEGG pathways with the use of our miRNA augmented pathways (mirAP).
We performed two pathway analysis methods that use p-value and fold-change for
each set of pathways: impact analysis (IA) [41, 140] and over-representation analysis
(ORA) [40]. The input for IA and ORA using KEGG is mRNA expression data. The
input for IA and ORA using mirAP includes both mRNA and miRNA expression
data. The output of each method is a list of p-values (one per each pathway). These
p-values are adjusted for multiple comparisons using the false discovery rate approach
(FDR) [10].
We also analyze the nine GEO datasets using microGraphite [19] after quantile
normalization [16] to compare with our pipeline. The primary goal of microGraphite
is the identification of signal transduction paths correlated with the condition under
study. It is implemented in a four-steps recursive procedure as follows: (i) selecting
pathways, (ii) best path identification, (iii) meta-pathway construction, and (iv) meta-
pathway analysis. Here we only consider the first step of the approach, which is the
selection of significant pathways. This selection is based on the significance levels
obtained from the test on the mean of the pathways (alpha-mean). The input is the
mRNA and miRNA expression data, and it does not take in account fold-changes nor
differentially expressed entities.
For each dataset, we expect a good method to identify the target pathway as
significant, as well as to rank it on top. For instance, in the colorectal cancer dataset
which compares colorectal cancer tissue vs. normal, the Colorectal cancer pathway
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Figure 6.3: Portion of the miRNA-augmented Amyotrophic Lateral Sclerosis pathway.
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Table 6.2: Results of target pathway identification using ORA (column 3), IA (col. 4),
ORA on mirAP (col. 5), IA on mirAP (col. 6), microGraphite (col. 7)
GEO ID Target pathway ORA IA ORAmir IAmir microG.
GSE26168 Type II diabetes mellitus no no no no yes
GSE29250 Non-small cell lung canc. no no yes no no
GSE35982 Colorectal cancer no no no no no
GSE32688 Pancreatic cancer no no yes yes no
GSE35389 Melanoma no no yes yes no
GSE35834 Colorectal cancer no no yes yes no
GSE43592 Amyotrophic lateral scle. no no no yes no
GSE43797 Pancreatic cancer no no yes yes yes
GSE62699 Alcoholism no no no yes no
must be shown as significant and should be as close to the top of the ranking as
possible since this is the pathway that describes the phenomena involved in colorectal
cancer. Based on this evaluation, we compared the rank and p-value of the target
pathway in each disease for five methods:
i) mRNA expression alone using standard KEGG pathways with ORA
ii) mRNA expression alone using standard KEGG pathways with IA
iii) mRNA and miRNA expression data using the augmented pathways (mirAP)
with ORA
iv) mRNA and miRNA expression data using mirAP with IA
v) mRNA and miRNA expression data analyzed with microGraphite.
Table 6.2 shows the target pathways and their significance for the nine datasets.
The first and second columns display the datasets and their corresponding target path-
ways while the other five columns indicate whether the target pathways are identified
as significant using the five methods: ORA of mRNA expression on KEGG pathways
(ORA+KEGG), IA of mRNA expression on KEGG (IA+KEGG), ORA of miRNA
and mRNA expression data on mirRNA-augmented pathways (ORA+mirAP), our
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approach IA of miRNA and mRNA expression on mirAP (IA+mirAP), and miRNA
and mRNA expression analysis using microGraphite, respectively. The significance
threshold is 5% for FDR p-values. IA and ORA fail to identify any target pathway
as significant when using just mRNA whereas our approach (IA+mirAP) correctly
identify the target pathway in 6 out of 9 datasets (GSE32688, GSE35389, GSE35834,
GSE43592, GSE43797, GSE62699). ORA on mirAP correctly identify the target
pathway as significant in 5 out of 9 datasets (GSE29250, GSE32688, GSE35389,
GSE35834, GSE43797). microGraphite correctly identifies the target pathway as sig-
nificant in only 2 out of 9 datasets (GSE26168, GSE43797). The results demonstrate
that our integration of mRNA and miRNA lifts the statistical power for both pathway
analysis techniques (ORA and IA) and outperforms microGraphite in target pathway
identification.
Figure 6.4 shows the p-values and rankings of the target pathways using the five
methods. The panel (a) shows the FDR corrected p-values of the target pathways. We
compare the lists of p-values using t-test and Wilcoxon test. The adjusted p-values
produced by IA+mirAP are significantly smaller than those of IA+KEGG (p=0.002
using t-test and p=0.007 using Wilcoxon test), ORA+KEGG (p=0.001 using the
t-test, and p=0.005 using Wilcoxon test), and microGraphite (p=0.006 using t-test
and p=0.009 using Wilcoxon test).
The panel (b) shows the rankings of the target pathways. Again, the rankings pro-
duced by IA+mirAP are significantly smaller than those of IA+KEGG (p=0.03 using
the t-test, and p=0.04 using Wilcoxon test), ORA+KEGG (p=0.03 using t-test and
p=0.04 using Wilcoxon test), and microGraphite (p=0.0051 using t-test and p=0.0058
using Wilcoxon test). This result confirms that our augmented pathways, mirAP, im-
prove the performance of traditional Impact Analysis and ORA. Also, the results
show that the proposed integrative pathway analysis also outperforms microGraphite
in both p-values and rankings for target pathway identification. Furthermore, our
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Figure 6.4: Corrected p-values and rankings of the target pathways using different meth-
ods.
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pathway database (mirAP) is generated with validated miRNA-mRNA interactions,
while microGraphite uses predicted interactions which increase the number of false
positive miRNA-target interactions. Another drawback of microGraphite is its ex-
ecution time. A typical analysis with microGraphite takes approximately 22 hours
while our approach takes only a few minutes. We ran these experiments on a standard
desktop workstation with a 2.6 GHz Intel Core i5, 8GB of RAM, on a single thread,
and the OS X 10.11 operative system.
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Chapter 7: Reference Manual






Title Integrating microRNA expression into signaling pathways for pathway analysis
Author Diana Diaz (dmd at wayne dot edu)
Maintainer Diana Diaz (dmd at wayne dot edu)
Depends R (>= 3.3)
Imports graph,ROntoTools, ggplot2, org.Hs.eg.db, AnnotationDbi, Rgraphviz
Suggests RUnit, BiocGenerics
Description Tools for augmenting signaling pathways to perform pathway analysis
of microRNA and mRNA expression levels.
License GPL (>=3)
URL http://datad.github.io/mirIntegrator/
biocViews Network, Microarray, GraphAndNetwork, Pathways, KEGG
NeedsCompilation no
augmented pathways
Signaling pathways augmented with miRNA.
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Description
Human signaling KEGG pathways augmented with validated miRNA-target in-
teractions from mirTarBase using the mirIntegrator package. These interactions
represent the biological miRNA repression of its target genes and are included in




A list of graphNEL objects where each graph is a pathway that was augmented
with miRNA-target interactions. The name of each pathway is its KEGG pathway
identifier.
Source
Generated using the mirIntegrator package. A script that con-
structs the augmented pathways object may be found in ‘inst/script-
s/get augmented pathways.R’, see the example.
References
M. Kanehisa and S. Goto, KEGG: Kyoto Encyclopedia of Genes and Genomes,
Nucleic Acids Research, vol. 28, pp. 27-30, January 2000.
S.-D. Hsu, Y.-T. Tseng, S. Shrestha, Y.-L. Lin, A. Khaleel, C.-H. Chou, C.-F.
Chu, H.-Y. Huang, C.-M. Lin, S.-Y. Ho, T.-Y. Jian, F.-M. Lin, T.-H. Chang,
S.-L. Weng, K.-W. Liao, I.-E. Liao, C.-C. Liu, and H.-D. Huang, miRTarBase
update 2014: an information resource for experimentally validated miRNA-target
interactions, Nucleic Acids Research, vol. 42, pp. D78 - D85, Jan. 2014.
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See Also








GSE43592 miRNA Top table of preprocessed miRNA of GSE43592 dataset.
Description
A data.frame with the Log fold change and p-value of preprocessed miRNA ex-




A data frame with 881 miRNAs with the following 8 variables: entre, ID, logFC,
AveExpr, t, P.Value, adj.P.Val, B.
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Source
Raw data obtained from http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE43592 and preprocessed with the limma package version 3.24.0.
References
M. Jernas, C. Malmestrom, M. Axelsson, I. Nookaew, H. Wadenvik, J. Lycke, and
B. Olsson,MicroRNA regulate immune pathways in t-cells in multiple sclerosis
(MS), BMC immunology, vol. 14, p. 32, 2013.
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W and Smyth GK (2015).
limma powers differential expression analyses for RNA-sequencing and microarray




GSE43592 mRNA Top table of preprocessed mRNA of GSE43592 dataset.
Description
A data.frame with the Log fold change and p-value of preprocessed mRNA ex-





A data frame with 19611 mRNAs with the following 8 variables: entre, ID, logFC,
AveExpr, t, P.Value, adj.P.Val, B.
Source
Raw data obtained from http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
acc=GSE43592 and preprocessed with the limma package version 3.24.0.
References
M. Jernas, C. Malmestrom, M. Axelsson, I. Nookaew, H. Wadenvik, J. Lycke, and
B. Olsson,MicroRNA regulate immune pathways in t-cells in multiple sclerosis
(MS), BMC immunology, vol. 14, p. 32, 2013.
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W and Smyth GK (2015).
limma powers differential expression analyses for RNA-sequencing and microarray




integrate mir Produce augmented pathways
Description
This function takes each pathway of the input list of signaling pathways and adds






A list of graph::graphNEL objects where each of the nodes is
named with ‘<gene ID>’ . Gene IDs used to identify the nodes
must be the same gene IDs used to identify the genes on the
miRNA-target interactions data.frame, targets db. i.e. If the
genes are identified by Entrez ID on the original pathways
graph::graphNEL list, then the targets db data.frame must
identify the genes by Entrez ID as well. Nodes of each
graph::graphNEL represent the genes involved in the pathway and
edges represent the biological interactions (activation or repres-
sion) among those genes (activation or repression).
targets db A data.frame with columns: ‘miRNA’ which names the miRNAs
and ‘Target.ID’ which gives the gene ID of the target gene. The
Gene IDs used to identify the “Target.ID” column must be the
same gene IDs used on the nodes of the original pathways. i.e.
If the genes are identified by Entrez ID on the original pathways
graph::graphNEL list, then the targets db data.frame must iden-
tify the genes by Entrez ID as well.
Value
Gene signaling pathways augmented with miRNA interactions. The augmented
pathways are contained in a list of graph::graphNEL objects where each of the
nodes is named with ‘<gene ID>’. Nodes of each graph::graphNEL represent
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genes and miRNAs involved in the pathway and edges represent the biological






kegg_pathways <- kegg_pathways[1:5] #delete this for augmenting all pathways.
augmented_pathways <- integrate_mir(kegg_pathways, mirTarBase)
kegg pathways List of KEGG signaling pathways of human.
Description
This dataset contains 149 KEGG human signaling pathways. The original path-
ways were parsed to a list of graphNEL objects using the ROntoTools package.





A list of graphNEL objects where each graph represents one KEGG signaling
pathway. The name of each pathway is its KEGG pathway identifier.
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Source
Obtained using the ROntoTools package Version 1.2.0 with KEGG database re-
lease 73.0+/01-03, Jan 2015. A script that constructs the kegg pathways object
may be found in ‘inst/scripts/get kegg pathways.R’, see the example.
References
M. Kanehisa and S. Goto, KEGG: Kyoto Encyclopedia of Genes and Genomes,
Nucleic Acids Research, vol. 28, pp. 27-30, January 2000.
C. Voichita, M. Donato, and S. Draghici, Incorporating gene significance in the
impact analysis of signaling pathways, in 2012 11th International Conference on








mirTarBase MicroRNA-target interactions in human.
Description
Dataset of miRNA-target interactions in human obtained from mirTarBase release





A data.frame with 39083 interactions and 9 variables. The columns needed for
this package are:
• miRNA: which contains the miRNA ID,
• Target.ID: contains the entrez ID of the gene targeted by the miRNA
Details
This dataset is licensed by its authors (Hsu et al.), see http://mirtarbase.mbc.
nctu.edu.tw/cache/download/LICENSE.
Value
A data.frame with human miRNA-targets interactions
Source
Downloaded from http://mirtarbase.mbc.nctu.edu.tw/ on 4/1/2015. A script
which downloads the file and constructs the mirTarBase object may be found in
‘inst/scripts/get mirTarBase.R’, see the example.
References
S.-D. Hsu, Y.-T. Tseng, S. Shrestha, Y.-L. Lin, A. Khaleel, C.-H. Chou, C.-F.
Chu, H.-Y. Huang, C.-M. Lin, S.-Y. Ho, T.-Y. Jian, F.-M. Lin, T.-H. Chang,
S.-L. Weng, K.-W. Liao, I.-E. Liao, C.-C. Liu, and H.-D. Huang, miRTarBase
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update 2014: an information resource for experimentally validated miRNA-target








names pathways List of KEGG signaling pathways’ names.
Description
Names of the KEGG signaling pathways in human obtained with the ROntoTools
package. The original KEGG pathways were published by Kanehisa Laboratories,




A list of KEGG signaling pathways’ names.
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Source
Obtained using the ROntoTools package Version 1.2.0 with KEGG database re-
lease 73.0+/01-03, Jan 2015. A script that constructs the names pathways object
may be found in ‘inst/scripts/get names pathways.R’, see the example.
References
M. Kanehisa and S. Goto, KEGG: Kyoto Encyclopedia of Genes and Genomes,
Nucleic Acids Research, vol. 28, pp. 27-30, January 2000.
C. Voichita, M. Donato, and S. Draghici, Incorporating gene significance in the
impact analysis of signaling pathways, in 2012 11th International Conference on








pathways2pdf Export augmented pathways to pdf
Description
This function creates a pdf file with plottings of a list of augmented pathways.
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Usage
pathways2pdf(original_pathways, augmented_pathways, pathway_names, file)
Arguments
original pathways
A list of graph::graphNEL objects where each of the nodes is
named with ‘<gene ID>’. Nodes of each graph::graphNEL rep-
resent the genes involved in the pathway and edges represent the
biological interactions (activation or repression) among those genes
(activation or repression).
augmented pathways
A list of graph::graphNEL objects where each of the nodes is
named with ‘<gene ID>’. Nodes of each graph::graphNEL rep-
resent genes and miRNAs involved in the pathway and edges rep-
resent the biological interactions (activation or repression) among
them.
pathway names
A list of names of the pathways identified by ‘<pathway ID>’.
file The name of the file where the plots will be saved.
Value








#The following instruction writes a pfd with three pathways
pathways2pdf(kegg_pathways[18:20],augmented_pathways[18:20],
names_pathways[18:20], "three_pathways.pdf")
#The following instruction writes a pfd with all the pathways:




Plotting of augmented pathway
Description
Functions for plotting a particular augmented pathway. In the plot, miRNAs that
were added to the original pathway are differentiated from proteins that were
originally in the pathway. Blue boxes represent the proteins that were part of the








A graph::graphNEL object where each of the nodes is named with
‘<gene ID>’. Nodes of each graph::graphNEL represent the genes
involved in the pathway and edges represent the biological inter-
actions (activation or repression) among those genes.
augmented pathway
A graph::graphNEL object where each of the nodes is named with
‘<gene ID>’. Nodes of each graph::graphNEL represent genes
aand miRNAs involved in the pathway and edges represent the
biological interactions (activation or repression) among them.
pathway name
The name of the pathway.
... Other arguments for the ‘<plotPathway2Colors>’ function.
Value










plot change Plotting the change in pathways order
Description
Function for plotting a lines plot of the difference in pathways’ order. The resul-
tant plot shows the comparison between the order of the original pathways and
the order of the augmented pathways. It also contains a line with the order dif-
ference (order of the augmented pathways minus order of the original pathways).
The order of a biological pathway is the number of genes that are involved in it.
Usage
plot_change(original_pathways, augmented_pathways, pathway_names, ...)
Arguments
original pathways
A list of graph::graphNEL objects where each of the nodes is
named with ‘<gene ID>’. Nodes of each graph::graphNEL rep-
resent the genes involved in the pathway and edges represent the
biological interactions (activation or repression) among those genes
(activation or repression).
augmented pathways
A list of graph::graphNEL objects where each of the nodes is
named with ‘<gene ID>’. Nodes of each graph::graphNEL rep-
resent genes and miRNAs involved in the pathway and edges rep-




A list of names of the pathways identified by ‘<pathway ID>’.
... Other arguments for the ‘<plotLines>’ function.
Value








smallest pathway Get the smallest pathway
Description
Find the pathway with the fewer number of nodes among a list of pathways. This





pathways A list of graph::graphNEL objects.
Value








Chapter 8: Discussion and Conclusion
In this thesis, we present the background for integrating multiple types of data
for the purpose of pathway analysis and propose a method to augment signaling
pathways with miRNA-target interactions. We also show that miRNA-augmented
pathways (mirAP) offer a more comprehensive view and a deeper understanding of
complex diseases. Our contributions include a pipeline that use mirAP to integrate
miRNA and mRNA expression data for the purpose of pathway analysis, a publicly
available database of miRNA-augmented pathways, and an open source Bioconductor
package (mirIntegrator).
We describe methods for integrating multiple types of data for the purpose of
pathway analysis. We classified these methods into two broad categories: topol-
ogy based and non-topology based approaches. Topology-based methods take into
consideration the topology and interactions between genes while non-topology based
approaches treat a pathway as a set of genes or entities. When integrating multi-omics
data, the existing pathways (designed for gene expression) are expanded to include
other data types. Integrative pathway analysis methods extend the current graphs by
adding new nodes, relations, and interactions. The added nodes and links represent
the new data types. Then, the integrated model can be analyzed using the classical
pathway analysis methods. The input for integrative pathway analysis includes the
expanded pathways and multi-omics data. However, one major drawback of the ex-
isting integrative pathway analysis methods is that they are slow due to the intensive
computation required by the graphical models. Graphical models were initially de-
signed for graphs with less than a hundred nodes. However, the number of entities
in biological data can include thousands of genes or molecules. Additionally, existing
approaches combine expression values that are measured on different technologies or
platforms. Combining expression values requires cross-platform normalization which
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increases the statistical error. To fill this gap, we integrate the data using p-values of
differentially expressed entities instead of expression values. The combination of p-
values provides a significant advantage as p-values and do not require cross-platform
normalization.
As miRNA expression data are becoming freely accessible, miRNA-mRNA in-
tegrative analyses are likely to become a routine. Our pathway analysis pipeline
augments gene-gene signaling pathways with miRNA-target interactions. Then we
perform a topology-based pathway analysis taking into consideration both types of
molecular data. To demonstrate the power of the integrative analysis, we compared
our approach (mirIntegrator) with the state of the art method, microGraphite, us-
ing nine sample-matched datasets that were assayed in independent labs. While
microGraphite failed to identify target pathways as significant for 7 out of 9, our
approach correctly identified the target pathway as significant in 6 out of 9 datasets.
Also, mirIntegrator produced significantly smaller p-values and rankings of the target
pathways. In summary, our pipeline outperforms the state of the art method for
identifying target pathways (smaller p-values and rankings of the target pathways).
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The identification of pathways that are involved in a particular phenotype helps
us understand the underlying biological processes. Traditional pathway analysis tech-
niques aim to infer the impact on individual pathways using only mRNA levels. How-
ever, recent studies showed that gene expression alone is unable to capture the whole
picture of biological phenomena. At the same time, MicroRNAs (miRNAs) are newly
discovered gene regulators that have shown to play an important role in diagnosis,
and prognosis for different types of diseases. Current pathway analysis techniques
do not take miRNAs into consideration. In this project, we investigate the effect of
integrating miRNA and mRNA expression in pathway analysis. In order to analyze
biological pathways using miRNA expression data, we developed a novel method that
augments KEGG pathways with microRNAs targeting genes. To validate our method,
we analyzed nine GEO datasets. We also performed the analyses using just mRNA as
well as using the integrative state-of-the-art method (microGraphite) to compare the
results. In each case, we monitored the position of the pathway describing the given
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